Press Releases

 Filter by Provider

Milano, Italy - September 08, 2026 - Every advancing clarinetist reaches the same crossroads. The student instrument that once felt friendly now feels like a ceiling: technique has outgrown the horn, and the next purchase matters more than any before it. Choose well, and the new instrument unlocks years of growth. Choose poorly, and an expensive step becomes an expensive frustration. It is the one purchase in a clarinetist's development that teachers, parents, and players all agree deserves real homework.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Not for distribution to United States newswire services or for dissemination in the United States.

Milano, Italy - September 08, 2026 - Flagship instruments carry a particular burden. They are expected not merely to perform well, but to define what a maker believes a clarinet should be—and then to prove it, night after night, in the hands of players who notice everything. A flagship cannot hide behind marketing, because the musicians who play it have spent entire careers learning to hear past marketing. The Rigo Camerino, the artist-grade grenadilla clarinet at the summit of the Rigo range, was built to carry exactly that burden.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

The Law Offices of Frank R. Cruz announces an investigation of Papa John’s International, Inc. (“Papa John’s” or the “Company”) (NASDAQ: PZZA) on behalf of investors concerning the Company’s possible violations of federal securities laws.

FlipHTML5’s free flipbook maker helps small businesses simplify digital publishing on a limited budget through document conversion and ready-to-use templates.

WINNIPEG, MB / ACCESS Newswire / September 8, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today announced that the design, rationale and baseline data from its MEND-PNPO Phase 3 study (ClinicalTrials.gov NCT04706013) are being presented at the 16th European Epilepsy Congress (EEC), taking place September 5-9, 2026, at the Megaron Athens International Conference Centre in Athens, Greece. MEND-PNPO is a pivotal trial evaluating MC-1 for the treatment of Pyridox(am)ine 5'-Phosphate Oxidase (PNPO) deficiency.

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Criteo S.A. (“Criteo” or the “Company”) (NASDAQ: CRTO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Houston, Texas, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Battalion Oil Corporation (NYSE American: BATL, "Battalion" or the "Company") today announced an equity investment in Collide Industrial Technologies Inc. ("Collide") and “Strategic Partner” designation. Collide provides an AI-native operations system purpose-built for oil and gas that automates high-value engineering and operational workflows across upstream, midstream, and oilfield services sectors. The system is designed to reduce operating costs, compress cycle times, and unlock critical data trapped in legacy systems.

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Lincoln Educational Services Corp. (“Lincoln” or the “Company”) (NASDAQ: LINC).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Blaize Holdings, Inc. (“Blaize” or the “Company”) (NASDAQ: BZAI).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

ZAP Surgical Systems, Inc., a global leader in non-invasive robotic brain surgery, today announced that GenesisCare will soon become the first cancer care provider in Australia to offer ZAP-X® Gyroscopic Radiosurgery® platform. The installation within GenesisCare’s centre at St Vincent’s Hospital Sydney, New South Wales, is expected to begin this month, with first patient treatments anticipated before year-end.

BEIJING, Sept. 09, 2026 (GLOBE NEWSWIRE) -- 17 Education & Technology Group Inc. (NASDAQ: YQ) (“17EdTech” or the “Company”), a leading AI-powered application service provider focused on personalized learning solutions, today announced its unaudited financial results for the second quarter of 2026.

Meaghan B. Murphy, a ChatGPT power user and mom, partners with OpenAI, in conjunction with D S Simon Media, on a nationwide media tour discussing how ChatGPT for Teens is designed to help teens think critically and learn, with built-in protections for teens and additional controls for parents

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Alibaba Group Holding Limited (“Alibaba” or the “Company”) (NYSE: BABA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

KBRA assigns preliminary ratings to 10 classes of mortgage-backed notes issued by PRKCM 2026-AFC6 Trust, a $327.8 million non-prime RMBS transaction. The underlying collateral consists of 793 residential mortgages, with fixed-rate mortgages (FRMs) and hybrid adjustable-rate mortgages (ARMs) representing 98.4% and 1.6% of the pool, respectively. The transaction includes a meaningful concentration of collateral that KBRA considers non-prime. All of the loans were originated by AmWest Funding Corporation, which also currently services the pool.

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of L3Harris Technologies, Inc. (“L3Harris” or the “Company”) (NYSE: LHX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. (“Emergent” or the “Company”) (NYSE: EBS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Fragrance Creators Adds Its Newest Member as the Category's Expansion Draws a New Generation of Companies Into Industry Advocacy

The Board of Directors of U.S. Bancorp (NYSE: USB) has declared a regular quarterly dividend of $0.54 per common share, payable October 15, 2026, to stockholders of record at the close of business on September 30, 2026. This is a dividend increase of 3.8 percent over the previous quarterly dividend per common share. At this quarterly dividend rate, the annual dividend is equivalent to $2.16 per common share.

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of SELLAS Life Sciences Group, Inc. (“Sellas” or the “Company”) (NASDAQ: SLS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. (“EyePoint” or the “Company”) (NASDAQ: EYPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Wolfspeed, Inc. (“Wolfspeed” or the “Company”) (NYSE: WOLF). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Pentair plc (“Pentair” or the “Company”) (NYSE: PNR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Klarna Group plc (“Klarna” or the “Company”) (NYSE: KLAR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HCA Healthcare, Inc. ("HCA" or the "Company") (NYSE: HCA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against UWM Holdings Corporation (“UWM” or the “Company”) (NYSE: UWMC).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Baidu, Inc. (“Baidu” or the “Company”) (NASDAQ: BIDU).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Park Ha Biological Technology Co., Ltd. (“Park Ha” or the “Company”) (NASDAQ: BYAH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against DNOW Inc. (“DNOW” or the “Company”) (NYSE: DNOW). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

Camden Property Trust (NYSE:CPT) (the “Company”) announced today that the Company will participate in the Evercore Real Estate Conference on September 10, 2026, the Barclays Global Financial Services Conference on September 14, 2026, and the BofA Securities Global Real Estate Conference on September 15-16, 2026. At the BofA conference, Camden’s Executive Team will host a roundtable discussion on Tuesday, September 15, 2026, at 2:15 PM Eastern Time. The event will be webcast live in a listen-only mode at camdenliving.com in the Investors section of the website, and an audio archive will be available shortly after the event concludes.

Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced top-line results from its randomized, double-blind, placebo controlled dose-ranging Phase 2b trial evaluating the efficacy and safety of oral Mas-related G-protein coupled receptor X2 (MRGPRX2) antagonist, EVO756, in adults with moderate-to-severe atopic dermatitis (AD).

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy’s Laboratories Limited (“Dr. Reddy’s” or the “Company”) (NYSE: RDY).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EHang Holdings Limited (“EHang” or the “Company”) (NASDAQ: EH).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ: AZTA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Rackspace Technology, Inc. (“Rackspace” or the “Company”) (NASDAQ: RXT).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of D-Wave Quantum Inc. (“D-Wave” or the “Company”) (NASDAQ: QBTS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Taboola.com Ltd. (“Taboola” or the “Company”) (NASDAQ: TBLA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Qfin Holdings, Inc. (“Qfin” or the “Company”) (NASDAQ: QFIN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. (“Sionna” or the “Company”) (NASDAQ: SION).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of OSI Systems, Inc. (“OSI” or the “Company”) (NASDAQ: OSIS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.